

HeartBeam secures an expedited FDA designation for its 3D ECG at-home heart attack assessment tool, paving the way for rapid clinical trials.
You can purchase shares of HeartBeam (NASDAQ:BEAT) through any online brokerage.
Other companies in HeartBeam’s space includes: Abbott Laboratories (NYSE:ABT), Intuitive Surgical Inc (NASDAQ:ISRG), Medtronic PLC (NYSE:MDT), Stryker Corp (NYSE:SYK) and Boston Scientific Corp (NYSE:BSX).
HeartBeam has a consensus price target of $4.00.
The stock price for HeartBeam (NASDAQ: BEAT) is $0.56 last updated October 30, 2026 at 7:55 PM EDT.
There are no upcoming dividends for HeartBeam.
HeartBeam does not have any upcoming earnings scheduled.
There is no upcoming split for HeartBeam.
HeartBeam is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's...